ASBP
Aspire Biopharma Holdings, Inc.
Biotechnology
Market Cap$9M
5Y Perf.-98.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ASBP vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.+178.5%
ASBP vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ASBP | MNMD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $9M | $2.04B |
| Revenue (TTM) | $2K | $0.00 |
| Net Income (TTM) | $-32M | $-184M |
| Gross Margin | 45.5% | — |
| Operating Margin | -10314.4% | — |
| Total Debt | $1M | $0.00 |
| Cash & Equiv. | $4K | $258M |
ASBP vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ASBP
MNMD
| Stock | Jan 25 | May 26 | Return |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBP) | 100 | 1.4 | -98.6% |
| Mind Medicine (Mind… (MNMD) | 100 | 278.5 | +178.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASBP vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNMD leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
ASBP
Aspire Biopharma Holdings, Inc.
The Specific-Use Pick
In this particular matchup, ASBP is outpaced on most metrics by others in the set.
Best for: healthcare exposure
MNMD
Mind Medicine (MindMed) Inc.
The Income Pick
MNMD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.68
- EPS growth -12.7%
- 5.1% 10Y total return vs ASBP's -98.4%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNMD | -64.9% revenue growth vs ASBP's -13.7% |
| Stability / Safety | MNMD | Beta 1.68 vs ASBP's 1.74 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNMD | +227.9% vs ASBP's -49.7% |
| Efficiency (ROA) | MNMD | -41.8% ROA vs ASBP's -13.2% |
ASBP vs MNMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNMDLAGGINGASBP
ASBPAspire Biopharma Hold…
0leads
MNMDMind Medicine (MindMe…
4leads
6 Total Categories
CATEGORYLEADERvs ASBPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
MNMD1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNMD4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
MNMD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
ASBP and MNMD operate at a comparable scale, with $1,941 and $0 in trailing revenue.
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… |
|---|---|---|
| RevenueTrailing 12 months | $1,941 | $0 |
| EBITDAEarnings before interest/tax | -$28M | -$156M |
| Net IncomeAfter-tax profit | -$32M | -$184M |
| Free Cash FlowCash after capex | -$4M | -$161M |
| Gross MarginGross profit ÷ Revenue | +45.5% | — |
| Operating MarginEBIT ÷ Revenue | -10314.4% | — |
| Net MarginNet income ÷ Revenue | -16352.0% | — |
| FCF MarginFCF ÷ Revenue | -1811.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | -22.0% |
Insufficient data to determine a leader in this category.
Valuation Metrics
MNMD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… |
|---|---|---|
| Market CapShares × price | $9M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $10M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.72x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — |
MNMD leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
MNMD leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), MNMD scores 3/9 vs ASBP's 2/9, reflecting mixed financial health.
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… |
|---|---|---|
| ROE (TTM)Return on equity | — | -55.3% |
| ROA (TTM)Return on assets | -13.2% | -41.8% |
| ROICReturn on invested capital | — | -3.9% |
| ROCEReturn on capital employed | — | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $1M | -$258M |
| Cash & Equiv.Liquid assets | $3,633 | $258M |
| Total DebtShort + long-term debt | $1M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -9.19x | -14.63x |
MNMD leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNMD five years ago would be worth $4,045 today (with dividends reinvested), compared to $162 for ASBP. Over the past 12 months, MNMD leads with a +227.9% total return vs ASBP's -49.7%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs ASBP's -74.7% — a key indicator of consistent wealth creation.
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… |
|---|---|---|
| YTD ReturnYear-to-date | +35.8% | +51.7% |
| 1-Year ReturnPast 12 months | -49.7% | +227.9% |
| 3-Year ReturnCumulative with dividends | -98.4% | +510.3% |
| 5-Year ReturnCumulative with dividends | -98.4% | -59.6% |
| 10-Year ReturnCumulative with dividends | -98.4% | +512.1% |
| CAGR (3Y)Annualised 3-year return | -74.7% | +82.7% |
MNMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
MNMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MNMD is the less volatile stock with a 1.68 beta — it tends to amplify market swings less than ASBP's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs ASBP's 7.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 1.68x |
| 52-Week HighHighest price in past year | $2.45 | $21.09 |
| 52-Week LowLowest price in past year | $0.05 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +7.6% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 30.3 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 11.8M | 806K |
MNMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ASBPAspire Biopharma … | MNMDMind Medicine (Mi… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $20.00 |
| # AnalystsCovering analysts | — | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNMD leads in 4 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency.
Best OverallMind Medicine (MindMed) Inc. (MNMD)Leads 4 of 6 categories
Loading custom metrics...
ASBP vs MNMD: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ASBP or MNMD a better buy right now?
Analysts rate Mind Medicine (MindMed) Inc.
(MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ASBP or MNMD?
Over the past 5 years, Mind Medicine (MindMed) Inc.
(MNMD) delivered a total return of -59. 6%, compared to -98. 4% for Aspire Biopharma Holdings, Inc. (ASBP). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus ASBP's -98. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ASBP or MNMD?
By beta (market sensitivity over 5 years), Mind Medicine (MindMed) Inc.
(MNMD) is the lower-risk stock at 1. 68β versus Aspire Biopharma Holdings, Inc. 's 1. 74β — meaning ASBP is approximately 3% more volatile than MNMD relative to the S&P 500.
04Which has better profit margins — ASBP or MNMD?
Mind Medicine (MindMed) Inc.
(MNMD) is the more profitable company, earning 0. 0% net margin versus -16352. 0% for Aspire Biopharma Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -10314. 4% for ASBP. At the gross margin level — before operating expenses — ASBP leads at 45. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ASBP or MNMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ASBP or MNMD better for a retirement portfolio?
For long-horizon retirement investors, Mind Medicine (MindMed) Inc.
(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Aspire Biopharma Holdings, Inc. (ASBP) carries a higher beta of 1. 74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, ASBP: -98. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ASBP and MNMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.